Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Osteoporosis in men.

Watts NB.

Endocr Pract. 2013 Sep-Oct;19(5):834-8. doi: 10.4158/EP13114.RA. Review.

PMID:
23757624
2.

Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.

Lindsay R, Watts NB, Lange JL, Delmas PD, Silverman SL.

Osteoporos Int. 2013 Aug;24(8):2345-52. doi: 10.1007/s00198-013-2332-7. Epub 2013 Apr 24. Erratum in: Osteoporos Int. 2013 Aug;24(8):2375-6.

PMID:
23612793
3.

Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence.

Eastell R, Vrijens B, Cahall DL, Ringe JD, Garnero P, Watts NB.

J Bone Miner Res. 2011 Jul;26(7):1662-9. doi: 10.1002/jbmr.342.

4.

Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.

Ferrari S, Nakamura T, Hagino H, Fujiwara S, Lange JL, Watts NB.

J Bone Miner Metab. 2011 Sep;29(5):561-70. doi: 10.1007/s00774-010-0249-1. Epub 2011 Jan 12.

PMID:
21225297
5.

Long-term use of bisphosphonates in osteoporosis.

Watts NB, Diab DL.

J Clin Endocrinol Metab. 2010 Apr;95(4):1555-65. doi: 10.1210/jc.2009-1947. Epub 2010 Feb 19. Review.

PMID:
20173017
6.

Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placebo.

Watts NB, Brown JP, Cline G.

J Clin Densitom. 2010 Jan-Mar;13(1):56-62. doi: 10.1016/j.jocd.2009.09.005. Epub 2009 Nov 26.

PMID:
19942469
7.

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.

Miller PD, Delmas PD, Lindsay R, Watts NB, Luckey M, Adachi J, Saag K, Greenspan SL, Seeman E, Boonen S, Meeves S, Lang TF, Bilezikian JP; Open-label Study to Determine How Prior Therapy with Alendronate or Risedronate in Postmenopausal Women with Osteoporosis Influences the Clinical Effectiveness of Teriparatide Investigators.

J Clin Endocrinol Metab. 2008 Oct;93(10):3785-93. doi: 10.1210/jc.2008-0353. Epub 2008 Aug 5.

8.

Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.

Hounslow AM, Carran J, Brown RJ, Rejman D, Blackburn GM, Watts DJ.

J Med Chem. 2008 Jul 24;51(14):4170-8. doi: 10.1021/jm7015792. Epub 2008 Jul 1.

PMID:
18590315
9.

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

Russell RG, Watts NB, Ebetino FH, Rogers MJ.

Osteoporos Int. 2008 Jun;19(6):733-59. doi: 10.1007/s00198-007-0540-8. Review.

PMID:
18214569
10.

Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy.

Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, Kavanagh KL, Triffitt JT, Lundy MW, Phipps RJ, Barnett BL, Coxon FP, Rogers MJ, Watts NB, Ebetino FH.

Ann N Y Acad Sci. 2007 Nov;1117:209-57. Review.

PMID:
18056045
11.

Fracture risk remains reduced one year after discontinuation of risedronate.

Watts NB, Chines A, Olszynski WP, McKeever CD, McClung MR, Zhou X, Grauer A.

Osteoporos Int. 2008 Mar;19(3):365-72. Epub 2007 Oct 16.

PMID:
17938986
12.

Assessment of non-vertebral fracture risk in postmenopausal women.

Roux C, Briot K, Horlait S, Varbanov A, Watts NB, Boonen S.

Ann Rheum Dis. 2007 Jul;66(7):931-5. Epub 2007 Feb 21.

13.

Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.

Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB; Improving Measurements of Persistence on Actonel Treatment (IMPACT) Investigators.

J Clin Endocrinol Metab. 2007 Apr;92(4):1296-304. Epub 2007 Jan 23. Erratum in: J Clin Endocrinol Metab. 2007 Jun;92(6):2285.

PMID:
17244788
14.

Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.

Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R.

Osteoporos Int. 2007 Jan;18(1):25-34. Epub 2006 Nov 15.

15.

Review of treatment modalities for postmenopausal osteoporosis.

Hamdy RC, Chesnut CH 3rd, Gass ML, Holick MF, Leib ES, Lewiecki ME, Maricic M, Watts NB.

South Med J. 2005 Oct;98(10):1000-14; quiz 1015-7, 1048. Review.

PMID:
16295815
16.
17.

Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.

Boonen S, Laan RF, Barton IP, Watts NB.

Osteoporos Int. 2005 Oct;16(10):1291-8. Epub 2005 Jun 29. Review.

PMID:
15986101
18.
19.

Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.

Harris ST, Watts NB, Li Z, Chines AA, Hanley DA, Brown JP.

Curr Med Res Opin. 2004 May;20(5):757-64. Erratum in: Curr Med Res Opin. 2004 Oct;20(10):1690.

PMID:
15140343
20.

Efficacy of risedronate on clinical vertebral fractures within six months.

Roux C, Seeman E, Eastell R, Adachi J, Jackson RD, Felsenberg D, Songcharoen S, Rizzoli R, Di Munno O, Horlait S, Valent D, Watts NB.

Curr Med Res Opin. 2004 Apr;20(4):433-9.

PMID:
15119979

Supplemental Content

Loading ...
Support Center